Press Releases May 27, 2026 01:00 AM

argenx to Present at Upcoming Investor Conferences

argenx Management to Present at Major Investor Conferences in June 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
ARGX

argenx announced its participation in two prominent investor conferences in June 2026, including the William Blair 46th Annual Growth Stock Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The presentations will highlight the company’s progress in immunology and its pipeline of novel antibody-based medicines targeting severe autoimmune diseases.

argenx to Present at Upcoming Investor Conferences
ARGX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • argenx will present at two major investor conferences in June 2026, providing updates on its business and pipeline.
  • The company is focused on developing novel antibody-based treatments targeting severe autoimmune diseases, including the commercialization of the first approved neonatal Fc receptor (FcRn) blocker.
  • Live webcasts will be available, increasing accessibility to investors and stakeholders globally.


May 27, 2026

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in June:

  • William Blair 46th Annual Growth Stock Conference. Presentation on Wednesday, June 3, 2026 at 12:40 p.m. CT in Chicago, IL.
  • Goldman Sachs 47th Annual Global Healthcare Conference. Fireside chat on Tuesday, June 9, 2026 at 4:00 p.m. ET in Miami, FL.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  www.argenx.com  and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts

Media:

Ben Petok
[email protected]

Investors:

Alexandra Roy
[email protected]


Risks

  • The success and market acceptance of argenx’s antibody-based medicines, including the FcRn blocker, remain subject to clinical, regulatory, and commercial uncertainties.
  • Competition within the immunology and autoimmune disease treatment sectors may impact argenx’s growth and market share.
  • Investment community interest and stock reaction can be influenced by the ability of management to communicate promising clinical and commercial progress during these conferences.

More from Press Releases

Trump Media Settles Legal Disputes Jul 19, 2026 GEnx-1B Engines Surpass 50 Million Flight Hours Jul 19, 2026 XA Investments President Kimbery Flynn Speaks to Shareholders About XFLT Proxy Vote Jul 19, 2026 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population Jul 18, 2026 UFC Names Meridian Holdings Official Sponsor of Fight Night Belgrade Jul 18, 2026